p53 Protein News and Research

RSS

The TP53 is a gene that instructs the cell to produce tumor protein (p53) ; a vital transcription factor and tumor suppressor. P53 is known as the “guardian of the genome” as it helps in regulating the cell cycle and acts as a tumor suppressor.

Roche Molecular Systems, Merck Sharp & Dohme announce cancer therapeutics collaboration

Roche Molecular Systems, Inc. announced today a research collaboration with Merck Sharp & Dohme Corp. (a subsidiary of Merck & Co., Inc.) providing Merck access to Roche's developmental microarray-based AmpliChip p53 Test, which is designed to detect mutations in the tumor suppressor gene p53. By identifying cancers that harbor a dysfunctional p53 gene, the companies aim to achieve better treatment outcomes in cancer patients by determining which patients are most likely to respond to certain investigational therapeutic candidates.

18 Feb 2010

Cancer Research UK scientists named on New Year's Honours list

Several of Cancer Research UK's scientists have been named on this year's New Year's Honours list, as has the government's National Cancer Director and a long-term supporter of the charity.

9 Jan 2010

Champions Biotechnology and Ramot establish licensing agreement

Champions Biotechnology, Inc., a U.S. Oncology drug development company with a predictive preclinical platform aimed at accelerating the development and enhancing the value of oncology drugs, has established an exclusive licensing agreement with Ramot at Tel Aviv University Ltd., Tel Aviv University's wholly owned technology transfer company.

2 Dec 2009

Activating TAp63 protein, a viable anti-cancer strategy

Oncologists have had their hands tied because more than half of all human cancers have mutations that disable a protein called p53. As a critical anti-cancer watchdog, p53 masterminds several cancer-fighting operations within cells. When cells lose p53, tumors grow aggressively and often cannot be treated.

10 Nov 2009

Champions Biotechnology obtains global rights to Tel Aviv University's TAR-1 compound

Champions Biotechnology, Inc., an oncology drug development company with a predictive preclinical platform aimed at accelerating the development and enhancing the value of oncology drugs, has established an exclusive licensing agreement with Ramot at Tel Aviv University Ltd., Tel Aviv University's wholly owned technology transfer company.

27 Oct 2009

Estrogen can reduce stroke damage by inactivating a tumor-suppressing protein

Estrogen can halt stroke damage by inactivating a tumor-suppressing protein known to prevent many cancers, Medical College of Georgia researchers say.

17 Jul 2009

Dramatic drop in deaths from most common cancers

The death toll from three of the UK's most common cancers has dropped to its lowest level for almost 40 years* - according to new figures released by Cancer Research UK.

12 Jul 2009

Discovery of potent metastasis inhibitor

Researchers at Children's Hospital Boston have isolated a potent inhibitor of tumor metastasis made by tumor cells, one that could potentially be harnessed as a cancer treatment.

23 Jun 2009

Study gives clues to how ultra-rare adrenocortical cancer forms

At the ends of chromosome are special pieces of DNA called telomeres. Think of it as the little tip that caps off a shoelace. The telomeres send signals to the cells to let them know it's the end point, not a break that should be repaired.

4 Jun 2009

Glioblastoma may originate in neural stem cells

University of Michigan scientists have found that a deficiency in a key tumor suppressor gene in the brain leads to the most common type of adult brain cancer. The study, conducted in mice that mimic human cancer, points the way to more effective future treatments and a way to screen for the disease early.

1 Jun 2009

Nanoparticle delivery of a fully functioning copy of P53 tumor suppressor gene

Dr. Esther Chang describes the most recent developments in human trials of the first systemic, non-viral, tumor-targeted, nanoparticle method designed to restore normal gene function to tumor cells while completely bypassing normal tissue April 21 at an American Association of Anatomists (AAA) scientific session at Experimental Biology 2009 in New Orleans.

20 Apr 2009

Chemopreventive isothiocyanates selectively depletes mutant p53 in tumor cells

Researchers at Lombardi Comprehensive Cancer Center at Georgetown University Medical Center have demonstrated that naturally-occurring compounds can selectively deplete mutant p53 and restore "wild type" function to p53 in a variety of tumor cells.

20 Apr 2009

Research shows how p53 mutations link to high-grade breast cancer, poor outcomes

In what is believed to be the largest study of its kind in the US, researchers have found that almost 26 percent of women studied who have breast cancer have mutations in a gene important in controlling cell growth and death, and that patients with mutations in this gene - known as p53 - had poorer outcomes including a significantly increased risk of death from the cancer.

20 Apr 2009

SIRT1 takes down tumors

Yuan et al. have identified another anti-cancer effect of the "longevity" protein SIRT1.

13 Apr 2009

AVEO Pharmaceuticals announces findings from novel human-in-mouse cancer model system

AVEO Pharmaceuticals, Inc. has announced findings from its novel human-in-mouse (HIM) cancer model system, in which AVEO successfully created invasive human tumors from primary human breast tissue that develop over time in mice and mimic human tumor behaviors and response.

6 Apr 2009

Discovery of marker for severity in adult brain cancer

Researchers at UT Southwestern Medical Center have identified a new biological indicator that may help identify which brain-cancer patients have the most aggressive forms of the disease.

1 Apr 2009

Possible genetic cause for advanced colorectal cancer in blacks

Researchers have identified a possible genetic cause for increased risk for a more advanced form of colorectal cancer in blacks that leads to shorter survival, according to data published in Clinical Cancer Research , a journal of the American Association for Cancer Research.

1 Apr 2009

Researchers develop mouse models of leukemia that predict response to chemotherapy

Being able to accurately predict how a given cancer will respond to chemotherapy would spare patients with non-responsive tumors the burden of undergoing toxic and ultimately unhelpful treatment.

1 Apr 2009

Discovery of major new risk factor for melanoma in young women

Researchers may have found a more potent risk factor for melanoma than blistering sunburns, freckling, or family history of the deadly skin disease.

24 Mar 2009

MicroRNA undermines tumor suppression

Scientists at the Whitehead Institute for Biomedical Research and the National University of Singapore have discovered the first microRNA (miRNA) capable of directly tamping down the activity of the well known tumor-suppressor gene, p53, While p53 functions to prevent tumor formation, the p53 gene is thought to malfunction in more than 50% of cancerous tumors.

17 Mar 2009